VIVUS Earnings Preview: 3 Things to Watch
Instead of celebrating VIVUS' drug launch last quarter, shareholders were shocked to hear the company report thin sales and see the stock's share price cut by a whopping 20%. The company is set to report its fourth-quarter results -- the first full quarter featuring Qsymia sales -- on Feb. 25, and investors are wondering whether this biotech can regain its momentum. Should they continue tracking sales, or are there other issues that deserve equal attention? Health-care analyst Max Macaluso dives into this topic in the following video.
Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this drugmaker or whether now is the perfect time to sell. In a new premium research report, the Fool's top health-care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report -- complete with a full year of free updates -- click here now.
The article VIVUS Earnings Preview: 3 Things to Watch originally appeared on Fool.com.Max Macaluso, Ph.D., and The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.